[EFFECT] Aditxt, Inc. SEC Filing

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

EFFECT

Rhea-AI Filing Summary

07/01/2025 - 12:15 AM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date:	June 30, 2025 4:30 P.M.

Form:

S-1

CIK:	0001726711
Company Name:	Aditxt, Inc.
File Number:	333-288211

Source: View Original Filing on SEC EDGAR

Aditxt Inc

NASDAQ:ADTX

ADTX Rankings

#9406 Ranked by Market Cap

N/A Ranked by Dividends

ADTX Latest News

Jun 11, 2025

Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting

Jun 9, 2025

Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of Directors

Jun 5, 2025

Saundra Pelletier, Evofem Biosciences’ CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

May 19, 2025

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

May 2, 2025

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

ADTX Latest SEC Filings

Jul 1, 2025

[8-K] Aditxt, Inc. Reports Material Event

Jun 30, 2025

[424B3] Aditxt, Inc. Prospectus Filed Pursuant to Rule 424(b)(3)

Jun 25, 2025

[8-K] Aditxt, Inc. Reports Material Event

Jun 20, 2025

[S-1] Aditxt, Inc. Files IPO Registration Statement

ADTX Stock Data

Market Cap 3.96M

Float 2.43M

Institutions Ownership 0.03%

Short Percent 12.42%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City RICHMOND